N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.27 NOK -2.24% Market Closed
Market Cap: 741.3m NOK

Nykode Therapeutics ASA
Effect of Foreign Exchange Rates

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nykode Therapeutics ASA
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Effect of Foreign Exchange Rates
$4.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Circio Holding ASA
OSE:CRNA
Effect of Foreign Exchange Rates
kr26k
CAGR 3-Years
-79%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Effect of Foreign Exchange Rates
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zelluna ASA
OSE:ZLNA
Effect of Foreign Exchange Rates
kr490k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
742.3m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.49 NOK
Overvaluation 78%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
4.2m USD

Based on the financial report for Sep 30, 2025, Nykode Therapeutics ASA's Effect of Foreign Exchange Rates amounts to 4.2m USD.

What is Nykode Therapeutics ASA's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 1Y
737%

Over the last year, the Effect of Foreign Exchange Rates growth was 737%.

Back to Top